|
Key
Features: |
|
| Title and year of the Document | Guidelines for Preparing A Health Economic Evaluation (March, 2009) |
| Affiliation of authors | Ministry of Social Affairs and Health |
| Main policy objective | Assist submission to the Pharmaceuticals Pricing Board. A health economic evaluation is obligatory in applications for the reimbursement status and a reasonable wholesale price for medicinal products containing a new active substance |
| Standard reporting format included | No |
| Disclosure | Not stated |
| Target audience of funding/ author’s interests | Pharmaceutical companies and contracted health economists preparing economic analyses for the Pharmaceuticals Pricing Board |
| Perspective | Societal |
| Indication | Indication approved for the medicinal product for which reimbursement status is applied or, if there are several indications, the most important one or ones |
| Target population | Clearly specified |
| Subgroup analysis | Yes |
| Choice of comparator | To be replaced product, most commonly used treatment, the best or minimum therapy. Need justification |
| Time horizon | Sufficiently long to permit an evaluation of all the essential costs and health effects |
| Assumptions required | Clearly recorded and justified |
| Preferred analytical technique | Any one of CMA, CEA, CUA, CBA |
| Costs to be included | All direct health care costs and comparable social welfare costs. Indirect costs shall be presented separately |
| Source of costs | Reflect Finnish conditions |
| Modeling | Yes |
| Systematic review of evidences | Not stated |
| Preference for effectiveness over efficacy | Yes |
| Preferred outcome measure | Not stated |
| Preferred method to derive utility | Not stated |
| Equity issues stated | Not stated |
| Discounting costs | 3% and 0% |
| Discounting outcomes | 3% and 0% |
| Sensitivity analysis-parameters and range | On uncertain parameters at credible range |
| Sensitivity analysis-methods | Not stated |
| Presenting results | Total and incremental costs and benefits. The various phases and results of the analysis shall be presented in such a way as to enable the reader to verify the essential effects on health and the costs related to the therapies at issue |
| Incremental analysis | Yes |
| Total C/E | Yes |
| Portability of results (Generalizability) | Not stated |
| Financial impact analysis | No |
| Mandatory or recommended or voluntary | The evaluation shall be prepared in accordance with the guidelines |
